MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202627076628 A) filed by Mabwell Shanghai Bioscience Co. , Ltd. on June 20, 2026, for Antibody Targeting Cxcr6 And Use Thereof.
Inventors include Li, Zhongfei; Ren, Wei; Yuan, Weilin; Liu, Chuang; Gui, Xun; and Liu, Datao.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The present invention provides an anti-CXCR6 antibody and the use thereof. The anti-CXCR6 antibody can bind to CXCR6 with high affinity and high specificity, has cross-species binding activity to both human CXCR6 and monkey CXCR6, is a clearing antibody targeting CXCR6, and has the potential of treating inflammation or immune disorder diseases. Compared with existing CXCR6 antibodies, the anti-CXCR6 antibody involves lower cell non-specific binding activity, lower off-target toxicity and higher safety.
Disclaimer: Curated by HT Syndication.
